Daniel Goldstein, MD, from Davidoff Cancer Center, Petah Tikva, Israel, talks to us about the possibility of lowering the current FDA-approved dose of pembrolizumab for the treatment of PD-L1-positive lung cancer and notes that studies have shown equivalent efficacies of the drug in two different doses. He states that lowering the prescription dose from 200mg, the FDA-approved dose, to 150mg, may save $0.8 billion annually, whilst maintaining the same level of efficacy in patients. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.